<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="brief-report" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of microbiology, epidemiology and immunobiology</journal-id><journal-title-group><journal-title xml:lang="en">Journal of microbiology, epidemiology and immunobiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Журнал микробиологии, эпидемиологии и иммунобиологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0372-9311</issn><issn publication-format="electronic">2686-7613</issn><publisher><publisher-name xml:lang="en">Central Research Institute for Epidemiology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">13614</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title xml:lang="en">SORPTION PROPERTIES OF VARIOUS POLYSACCHARIDE MATRIXES TO LACTOBACILLUS PLANTARUM 8RA-3 BACTERIA</article-title><trans-title-group xml:lang="ru"><trans-title>ОБРАЗОВАНИЕ АНТИТЕЛ К НЕЙРАМИ-НИДАЗЕ ВИРУСА ГРИППА А/КАЛИФОР-НИЯ/07/2009 (H1N1) ПОСЛЕ ИММУНИЗАЦИИ ЖИВОЙ ГРИППОЗНОЙ МОНОВАЛЕНТНОЙ ВАКЦИНОЙ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Smolonogina</surname><given-names>T. A</given-names></name><name xml:lang="ru"><surname>Смолоногина</surname><given-names>Т. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Desheva</surname><given-names>Yu. A</given-names></name><name xml:lang="ru"><surname>Дешева</surname><given-names>Ю. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shaldzhyan</surname><given-names>A. A</given-names></name><name xml:lang="ru"><surname>Шалджян</surname><given-names>А. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Grudinin</surname><given-names>M. P</given-names></name><name xml:lang="ru"><surname>Грудинин</surname><given-names>М. П</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rudenko</surname><given-names>L. G</given-names></name><name xml:lang="ru"><surname>Руденко</surname><given-names>Л. Г</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Institute of Experimental Medicine</institution></aff><aff><institution xml:lang="ru">НИИ экспериментальной медицины</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Research Institute of Influenza</institution></aff><aff><institution xml:lang="ru">НИИ гриппа</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2011-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2011</year></pub-date><volume>88</volume><issue>6</issue><issue-title xml:lang="en">NO6 (2011)</issue-title><issue-title xml:lang="ru">№6 (2011)</issue-title><fpage>72</fpage><lpage>76</lpage><history><date date-type="received" iso-8601-date="2023-06-09"><day>09</day><month>06</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2011, Smolonogina T.A., Desheva Y.A., Shaldzhyan A.A., Grudinin M.P., Rudenko L.G.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2011, Смолоногина Т.А., Дешева Ю.А., Шалджян А.А., Грудинин М.П., Руденко Л.Г.</copyright-statement><copyright-year>2011</copyright-year><copyright-holder xml:lang="en">Smolonogina T.A., Desheva Y.A., Shaldzhyan A.A., Grudinin M.P., Rudenko L.G.</copyright-holder><copyright-holder xml:lang="ru">Смолоногина Т.А., Дешева Ю.А., Шалджян А.А., Грудинин М.П., Руденко Л.Г.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://microbiol.crie.ru/jour/article/view/13614">https://microbiol.crie.ru/jour/article/view/13614</self-uri><abstract xml:lang="en"><p>Aim. Detection of antibodies against neuraminidase (NA) of A/California/07/2009 (H1N1) influenza virus in blood sera of volunteers after the immunization with live monovalent influenza vaccine (LIV). Materials and methods. Neuraminidase enzyme activity inhibition by antibodies test with reassortant strain A(H7N1) containing NA of pandemic strain was used. Antineuraminidase IgG antibodies against whole reassortant virus A(H7N1) and purified NA ofA/California/07/2009 (H1N1) strains were determined by enzyme immunoassay (EIA). Results. After two immunizations with LIV of seronegative individuals a 1.5 times mean increase of antibodies against homologous neuraminidase was detected (by hemagglutinin inhibition reaction). The high level of anti-neuraminidase antibodies were detected in individuals that had been naturally infected. A correlation between anti-neuraminidase IgG antibody titers obtained in EIA with whole reassortant virus A(H7N1) and purified protein was demonstrated. Conclusion. Modified sialidase activity inhibition method and EIA with reassortant diagnostic strain can be applied to evaluate anti-neuraminidase antibodies.</p></abstract><trans-abstract xml:lang="ru"><p>Цель. Выявление антител к нейраминидазе (NA) вируса гриппа А/Калифор-ния/07/2009 (НШ1) в сыворотках крови волонтеров после иммунизации живой гриппозной моновалентной вакциной (ЖГВ). Материалы и методы. Использовали тест ингибирования антителами ферментативной активности нейраминидазы реассортантного вируса A(H7N1), содержащего NA пандемического штамма. В иммуноферментном анализе (ИФА) определяли антинейраминидазные IgG к цельному реассортантному вирусу A (H7N1) и очищенной NA штамма А/ Калифорния/07/2009 (Н1Ш). Результаты. После двукратного введения ЖГВ серонегативным лицам у них выявляли (в реакции торможения гемагглютинации) прирост антител к гомологичной нейраминидазе в среднем в 1,5 раза. Наиболее высокий уровень антинейраминидазных антител выявлен у лиц, перенесших естественную инфекцию. Показана корреляция между титрами антинейраминидазных IgG, полученными в ИФА с цельным реассортантным вирусом A(H7N1) и очищенным белком. Заключение. Модифицированный метод ингибирования сиалидазной активности и ИФА с реассортантным диагностическим штаммом применимы для оценки антинейраминидазных антител.</p></trans-abstract><kwd-group xml:lang="en"><kwd>influenza virus</kwd><kwd>neuraminidase</kwd><kwd>live influenza vaccine</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>вирус гриппа</kwd><kwd>нейраминидаза</kwd><kwd>живая гриппозная вакцина</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Ларионова Н.В., Киселева И.В., Руденко Л.Г. и др. Вакцинный штамм вируса гриппа А/17/Калифорния/2009/38 (H1N1) для производства живой гриппозной интраназальной вакцины для взрослых и детей. Заявка на изобретение № 2009 134 769, дата приема 16.09.09.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Aymard-Henry M., Coleman M.T., Dowdle WR. et al. Influenza virus neuraminidase and neuraminidase-inhibition test procedures. Bull. World Health Organ. 1973,48: 199-202.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Bright R.A., Neuzil K.M., Pervikov Y et al. WHO meeting on the role of neuraminidase in inducing protective immunity against influenza infection. Vaccine. 2009, 27: 6366-6369.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970, 227 (5259): 680-685.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Lambre C.R., Terzidis H., Greffard A. Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates. J. Immunol. Methods. 1990,135: 49-57.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Sandbulte M.R., Jimenez G.S., Boon A.C. et al. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Medicine. 2007, 4 (2): 265-272.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Shirvan A.N., Moradi M., Aminian M. et al. Preparation of neuraminidase-specific antiserum from the H9N2 subtype of avian influenza virus. Turk. J. Vet. Anim. Sci. 2007, 31 (4): 219-223.</mixed-citation></ref></ref-list></back></article>
